96 news articles
Evonetix collaborates with imec to scale-up chip-based technology production for third generation DNA synthesis platform
CAMBRIDGE, UK, and LEUVEN, Belgium, 13 January 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scala...
Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer
Macrophage Pharma Limited ("MPL"), a biotech company focused on the discovery and development of next-generation immunomodulatory small molecules indu...
Biotech firm MiAlgae secures £1m to turn whisky by-products into pet and fish food
An Edinburgh-based biotech startup which turns whisky distillation by-products into pet and fish food has received investment of £1 million.MiAlgae pr...
SynbiTECH2020 - Sponsor or Exhibit?
Happy new year! 2020 is the start of a new decade in which synthetic biology will thrive and grow – by 2030 we expect the global marketplace to be at ...
Kick off 2020 with a bang!
Don't miss our SUPER EARLY BIRD offer, ending 31st January! "Pretty much everyone we were looking to connect with in the synthetic biology and indust...
The SynbiCITE ‘4-Day MBA, More Business Acumen’ Course
The SynbiCITE ‘4-Day MBA: More Business Acumen’ Course, 8th-12th December 2019In 2015, 35% of employers in engineering and technology-based business s...
Data-driven design and the opportunities it presents for biotech companies
Professor Paul Freemont, Co-Director of SynbiCITE, discussed the synthetic biology industry and the opportunities it is creating in a recently paper published in The Emerging Topics in Life Sciences entitled “Synthetic biology industry: data-driven design is creating new opportunities in biotechnology”.
The Cell Factories of the Future
Professor Paul Freemont, Co-Director of SynbiCITE, is the lead author of a recent article published by the World Economic Forum on this subject, entitled “How scientists are turning living cells into the tiny factories of the future”.
SynbiTECH 2020 - Register your interest
SynbiTECH will return to London on 6-7th July 2020!To be kept up to date on ticket sales and conference announcements please register your interest he...
Prokarium secures £4.6m Wellcome funding for Entervax
Prokarium has announced an investment of £4.59 million from Wellcome to fund two clinical trials of its lead programme, Entervax.Follow this link for ...
Book before March 29th to receive 20% discount*
Building a multibillion-dollar synthetic biology industry The Synthetic Biology conference taking place in 2019, in London, that is not to be missed....
Evonetix establishes scientific advisory board
CAMBRIDGE, UK, 20 December 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fideli...
Synthetic biology start-up Colorifix raises $3m Series A round to scale its revolutionary textile dyeing solution
Colorifix, a company that has developed the first commercial biological dyeing process, has raised a Series A round of $3 million from impact and stra...
Addressing Global Challenges
Expert insights from SynbiCITE's leadership on the role of synthetic biology in solving some of the most significant challenges currently faced by our society
Evonetix wins Best Emerging Synthetic Biology Company at the OBN Awards
London, UK, 12th October 2018 / Sciad Newswire / SynbiCITE would like to congratulate Evonetix on winning ‘Best Emerging Synthetic Biology Company’ at...
Synthace launches ground-breaking new whitepaper
Comprehensive report heralds the beginning of Computer Aided Biology (CAB)LONDON October 01 2018 - Synthace Ltd., the company behind the leading cloud...
SynbiCITE launches new five-year strategy
SynbiCITE, the UK’s national centre for commercialisation of synthetic biology, launches a new five-year strategy underpinned by a new £5M grant from UKRI and other sources.
Evonetix makes key appointments to support development of novel gene synthesis technology
CAMBRIDGE, UK, 18 September 2018 – EVONETIX LTD (‘Evonetix’), the company pioneering an innovative approach to scalable and high-fidelity gene synthes...
Buildings made from fungi? Meet London’s pop-up bio-lab innovators
If there’s one place you wouldn’t expect a new biotech research lab to be built, it’s slap bang in the middle of a busy London marketFind out more her...
A Lloyd's Emerging Risk Report
Synthetic biology, the application of engineering principles to genetic modification is a market forecast to grow to $39bn by 2020. In recent years sc...
New competition - metasurfaces for defence and security
This themed competition is seeking proposals for innovative solutions that will pull ideas from recent breakthroughs in metasurface science into produ...
Global Biofoundry Meeting, London, June 2018
A meeting was held at Imperial College London on June 21st/22nd 2018, which gathered fifteenof the leading synthetic biology biofoundries from around the world to discuss current activities and exchange information on key capabilities and projects being developed by these groups.
If you missed the webinar you can catch up here https://synbiobeta.com/synbicite-webinarThe webinar highlighted findings from SynBioBeta’s 2018 Q2 inv...
RebelBio | Ready to change the world with biology?
RebelBio, the world’s first early-stage life-sciences accelerator, has opened their applications for the Winter Programme. Science graduates, PhDs, po...
SynbiCITE House of Lords Investor Breakfast
The SynbiCITE House of Lords Investor Breakfast was kindly hosted by The Lord Willetts - who instigated the Government’s ‘8 Great Technologies’ progra...
Save the date for our first Synthetic Biology Industrial Translation Showcase
The inaugural SynbiCITE – Synthetic Biology Industrial Translation Showcase will take place on Tuesday 5th June from 9.00am-5.00pm at the Royal Academy of Engineering
Prokarium secures $10 million investment
Prokarium secures $10 million investment from Saudi, Swedish and Korean investors for clinical development of revolutionary thermostable vaccinesKeele...
Transformational European Commission Grant dramatically accelerates novel biomaterial company Customem
CustoMem, founded in 2015 by two Imperial College London graduates, Henrik Hagemann and Gabi Santosa, has received a substantial €1.4m grant that will...
SynbiCITE welcomes RebelBio to London
We're the world's first early stage life sciences accelerator. Twice a year we invest up to $250K in startups solving global challenges with life itse...
Job Offers at Eligo Bioscience following $20M Funding Round
Breathing chandeliers and algae sculptures: bionic art comes to the V&A
Arborea, based in Imperial College’s White City innovation hub, has been featured in the Financial Times.
NPL and Imperial College London Launch a New Virtual Lab to Establish the UK Centre for Engineering Biology, Metrology and Standards
NPL, the UK's National Measurement Institute (NMI), and SynbiCITE at Imperial College London, have announced the establishment of a new £7 million virtual lab to underpin their joint Centre for Engineering Biology, Metrology and Standards to help the UK synthetic biology industry improve the manufacturing and adoption of new products - in partnership with LGC and NIBSC.
£17 million boost to the UK’s leading life sciences sector
The Chancellor of the Exchequer, Philip Hammond, announced this week £17million new funding will be supplied for UK life science, helping to create real benefits for the NHS and patients.
Synpromics announced as Best Emerging UK Synthetic Biotech Company at OBN Awards 2017
SynbiCITE congratulates Synpromics as the winner of Best Emerging UK Synthetic Biotech Company at OBN’s 9th Annual Awards.
Synthace raises £7.3m to accelerate biotechnology to enable faster breakthroughs
The Company’s Antha operating system brings end-to-end digitization to biotechnology, replacing current artisanal methods of development Speaking...
Synpromics expands facilities to meet demand for revolutionary gene control technology
Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre.
Three upcoming Innovation Funding competitions through InnovateUK
InnovateUK, the UK’s innovation agency, has three forthcoming Innovation Funding Competitions that opened recently.
World leading DNA technology is expanding its operations in London as it grows to meet global DNA demand
Touchlight Genetics Ltd has developed a revolutionary DNA technology that can synthetically manufacture commercial scale DNA in a two-week process – a...
A vibrant synthetic biology ecosystem has developed in the UK – promising new jobs and valuable technology
A survey of synthetic biology company start-ups in the UK is published today by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology. The study reveals a vibrant ecosystem sustaining a thriving and rapidly growing sector of the bioeconomy.
UK Synthetic Biology Start up Survey 2017
We would like to invite you to the Breakfast Seminar Launch of SynbiCITE’s UK Synthetic Biology Start-up Survey on Friday 21st July 2017, at 9.00-10:4...
CustoMem wins £100K 1st Prize in Bio-start competition
SynbiCITE and Rainbow Seed Fund congratulate CustoMem as winners of the 1st Prize in the Bio-start competition for companies using engineering biology to solve significant global problems.
Synpromics raises £5.2m of new investment
Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M. Participants included existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise and private shareholders.
Touchlight welcomes Dr. Geoff Smith
Touchlight is very pleased to welcome Dr. Geoff Smith as the Head of Innovations. Geoff brings extensive experience in genomics technologies and applications, with roles including Vice President leading Technology Development at Illumina and CEO of Cambridge Epigenetix.
Two new start-up plans win BrisSynBio’s first synthetic biology entrepreneurship competition
Two start-ups' proposals have been chosen as the winners of the first competition to discover and accelerate new synthetic biology companies at the University of Bristol.
Scientists engineer baker's yeast to produce penicillin molecules
The synthetic biologists from Imperial College London have re-engineered yeast cells to manufacture the nonribosomal peptide antibiotic penicillin. In laboratory experiments, they were able to demonstrate that this yeast had antibacterial properties against streptococcus bacteria.
Lab automation or robotic scientists: Dr McClymont and Professor Freemont share their views in Nature Biotechnology
Dr David McClymont, head of automation at the London DNA Foundry, and Professor Paul Freemont, Co-director of the London DNA Foundry and the EPSRC Cen...
East African Collaborations in Practical Synthetic Biology Workshop
From the 15th-17th March 2017 SynbiCITE will attend a workshop to establish UK-East African collaborations in practical synthetic biology, taking plac...
SynbiCITE is a proud sponsor of the ‘Best Emerging UK Synthetic Biology Company’ at the OBN Awards 2017
SynbiCITE is pleased to announce once again they will be sponsoring the ‘Best Emerging UK Synthetic Biology Company’ at the 9th Annual OBN Awards, 2017. This award recognises the emerging industrial or synthetic biology company that has the most promise.
Bio-start Selects First Cohort: 15 companies join Bio-start’s inaugural synthetic biology accelerator
Bio-start is pleased to announce the 15 companies that will be joining the UK’s first synthetic biology accelerator programme. Applicants from across ...
The London DNA Foundry Launches New Website
Based at Imperial College, the London DNA Foundry is a core facility at SynbiCITE, and has recently launched a new website.
Synpromics announces a research collaboration with GE Healthcare to Extend the Toolbox for Production of Biologics
Edinburgh, UK, 4th January 2017 / Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collabora...
Prokarium and Probiomed in UK-Mexico Collaboration to Scale-Up Manufacture of Thermostable Vaccines with a Focus on Diarrhoea
Keele, UK and Mexico City, MX, 4th January 2017 / Prokarium and Probiomed today announced the start of their collaboration to scale-up the manufacture...
Bio-start Competition Announces Additional Cash Prizes and Sponsors
SynbiCITE and Rainbow Seed Fund today announce new sponsors and prizes for the Bio-start competition, designed to commercialise the engineering of biology. The addition of new sponsors increases the number of prizes available to competitors including the free use of laboratory space around the UK.
LGC and Desktop Genetics receive SynbiCITE funding to develop novel methods for CRISPR genome editing analysis
Desktop Genetics and LGC have been awarded funding from SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, to develop screening and validation tools for functional genomics, cell line engineering and synthetic biology.
SynbiCITE response to Government announcement on extra investment for science
SynbiCITE welcomes yesterday’s announcement by the Government of an additional £2billion investment per year for UK science R&D by the end of this parliament. SynbiCITE Co-Director’s Professors Richard Kitney and Paul Fremont share their thoughts.
Synbio Start-up Accelerator and Mentoring Programme
Running from February – April 2017, the Bio-start accelerator will provide direct access to connections that matter most in the industry. All entrants accepted into the programme will receive substantial mentoring and exposure to our global business and investor network.
Professors Jay Keasling and Chris Voigt Announced as Keynote Speakers at the SynbiCITE & IET Engineering Biology Conference
The 1st International Conference on Engineering Biology, co-founded by SynbiCITE and the Institution of Engineering and Technology (IET), has announced world experts Professor Jay Keasling and Professor Chris Voigt as keynote speakers.
First look at the latest applications for Bio-start
Applications from a range of sectors across the UK continue to arrive for Bio-start, the competition to incentivise innovative early-stage companies a...
Touchlight Genetics announced as Best Emerging UK Synthetic Biotech Company at OBN Awards 2016
SynbiCITE congratulates Touchlight Genetics as the winner of Best Emerging UK Synthetic Biotech Company at the OBN’s 8th Annual Awards Ceremony held l...
Bio-start Confirms Sir Richard Sykes as Chair of Judging Panel
SynbiCITE and Rainbow Seed Fund today announce that Sir Richard Sykes, Chairman of the Royal Institution of Great Britain, Chairman of Imperial Colleg...
Future Innovations in Synthetic Biology Forum
The Institute of Child Health in London will host a Synthetic Biology Innovation Forum on 11th October 2016. This event will bring together leading Sy...
Bio-start Announces David Lawrence as Competition Finalist Judge
SynbiCITE and Rainbow Seed Fund today announce that Dr David Lawrence, Non-executive Director at Syngenta and Chairman of the Science and Technology A...
SynbiCITE Join BIA Promoting UK Companies at SynBioBeta, San Francisco 2016
SynbiCITE, along with the BIA – the UK’s biotechnology trade association - is headed to San Francisco, USA, to promote the UK synthetic biology industry to their American counterparts, as well as industry leaders and investors.
‘Building a Biotech Business from Scratch’: IBioIC announces a 4-day MBA ‘More Business Acumen’ from 20-24 November in Glasgow
The Industrial Biotechnology Innovation Centre (IBioIC), in association with SynbiCITE, will hold a 4-Day MBA in Glasgow from 20-24 November, aiming to develop the entrepreneurship of future biotechnology leaders.
Prokarium to Develop First Vaccine to Protect Against Sexually Transmitted and Insect-Borne Zika Infections
Keele, UK, 13th September 2016 / Prokarium today announced the start of its programme to develop an oral vaccine against Zika virus infection. Using t...
SynbiCITE to Sponsor ‘Best Emerging UK Synthetic Biotech Company’ Award at OBN Awards 2016
SynbiCITE is proud to be sponsoring the ‘Best Emerging UK Synthetic Biotech Company’ Award at the 2016 OBN awards on the 6rd of October.
SynbiCITE and Business Reporter release 'Nature Knows Best' Synthetic Biology Documentary
SynbiCITE has produced the synthetic biology documentary ‘Nature Knows Best’ in partnership with Business Reporter magazine.
SynbiCITE and Rainbow Seed Fund Announce New £200k Competition for Engineering Biology
SynbiCITE and Rainbow Seed Fund announce the launch of Bio-Start, an annual competition to support early stage companies in the field of synthetic biology.
OBN announce the finalists for Best Emerging UK Synthetic Biology Company
Oxitec winner of the 2015 Best Emerging UK SynBio Company OBN announced the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic B...
Prokarium receives £2M in Government contracts to develop new vaccines against emerging diseases and bioterrorist threats
Keele, UK, 25th July 2016 – Prokarium today announced the award of funding from the UK and Mexican Governments for the development of three new vaccin...
Cambridge Consultants spin-out Evonetix poised to transform synthetic biology industry
Cambridge Consultants announced the launch of a new DNA synthesis spin-out company, Evonetix. The joint venture, supported by technology entrepreneur ...
The UK’s First Bio-Hackathon to take place in Cambridge
The UK’s first Bio-Hackathon takes place in Cambridge this week from 21st – 25th June.
Applications Open for Lean Launchpad for Synthetic Biology 2016
SynbiCITE is now accepting applications for the next Lean Launchpad for Synthetic Biology, which will be run from September to November 2016.
Special offer to all SynbiCITE Partners Are you an early stage venture ready to accelerate your business? Want to be part of a global network of mento...
SynbiCITE Partner CustoMem wins 2016 Althea-Imperial Prize
Customem wins £10,000 for innovative use of synthetic biology to create membranes that filter pollutants from wastewater.
UK's First Commercial Synthetic Biology Foundry Goes Into Production
SynbiCITE has officially launched its synthetic biology Foundry, providing automated end-to-end design, construction and validation of synthetic biologic components.
Professor Paul Freemont on Radio 4
Professor Paul Freemont on BBC Radio 4 Today programme discussing latest development in synthetic biology following publication of Craig Venter's 'minimal genome' paper in Science
SynbiCITE Collaborator Bento Bioworks Completes Beta Testing
SynbiCITE collaborator and Lean Launchpad graduate Bento Bioworks has completed beta testing of Bento lab, their portable and affordable DNA lab, and have raised funding for their first production run.
'Living Factories of the Future' Featured in Nature
A recent feature in Nature focuses on the various ways industry and academia hope to automate and industrialise Synthetic Biology, including SynbiCITE's upcoming DNA Foundry.
Professor Paul Freemont delivers Ellison-Cliffe Lecture
You can now watch Synbicite co-director Professor Paul Freemont deliver the Royal Society of Medicine’s annual Ellison-Cliffe Lecture.
Watch George Freeman MP, Minister for Life Sciences, launch the new strategic plan for synthetic biology 'Biodesign for the Bioeconomy' at SynbiCITE
See and hear exactly what George Freeman MP, Minister for Life Sciences, said at the launch of the Synthetic Biology Strategic Plan 2016 - 'Biodesign for the Bioeconomy'
UK Strategic Plan for Synthetic Biology 2016 Released: Biodesign for the Bioeconomy
Minister for Life Sciences George Freeman MP visits SynbiCITE to announce the release of the UK Synthetic Biology Strategic Plan 2016 — Biodesign for the Bioeconomy.
Gen9 and SynbiCITE Announce Partnership to Accelerate Technology Commercialization through Synthetic Biology
Gen9 synthetic DNA to fuel innovations by SynbiCITE community
LabGenius wins SynbiCITE BlueSkyBio prize
LabGenius was chosen because of its development of a novel DNA library synthesis technology that allows it to construct DNA libraries that are more di...
SynbiCITE leads UKTI trade mission to SynBioBeta San Francisco 2015
SynbiCITE, along with 12 of the UK's leading synthetic biology companies, is headed to San Francisco, USA, to promote the UK synthetic biology industr...
Queen’s University Belfast and Ulster University team up with SynbiCITE to deliver a ‘launch pad’ for technology start-ups
The Lean LaunchPad is an import from Silicon Valley where it is used to ‘stress test’ the commercial feasibility of new innovations. Conceived by reti...
SynBioBeta Activate! Edinburgh 2015
Following news that synthetic biology companies have raised $500million in funding so far in 2015 (compared to $75million in 2009)1, it's clear that s...
SynbiCITE sponsors new award for synthetic biology
The winner is Oxitec and the award was announced last night, Thursday 1st October at the Ashmolean Museum in Oxford. Oxitec won the award for developi...
Dow AgroSciences and Synthace Collaborate Using Antha
The collaboration includes a multi-seat enterprise license giving Dow AgroSciences access to Synthace’s Antha software tools. As part of the agreement...
Start-ups take off at Lean LaunchPad 2
SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology based at Imperial College London, is running a new Lean Launchpad for buddin...
The 1st annual engineering biology awards recognise excellence in the synthetic biology industry at SynBioBeta SF 2015
The awards are being held at the upcoming SynBioBeta SF 2015 Conference that will be hosted at the Mission Bay Conference Center, in San Francisco, Ca...
SynbiCITE academics meet Imperial alumni in Beijing
Imperial's SynbiCITE academics (L-R: Guy-Bart Stan, Karen Polizzi, John Heap, Tom Ellis) address the alumni reunionSpeaking to alumni and friends, Pre...
Visbion awarded government grant from Innovate UK SMART initiative for Synthetic Biology project
Visbion are delighted to have been chosen as the recipient of a government grant via the Innovate UK SMART initiative for a new project entering into the field of synthetic biology.
New vaccine for Chlamydia to use synthetic biology
SynbiCITE funds Prokarium to complete pre-clinical development.
SynbiCITE and Imperial College London provides a launch pad for synthetic biology start-ups
The faculty team – left to right: Karl Handelsman (Codon Capital), Stephen Chambers (SynbiCITE), Itxaso del Palacio (Lepe Partners), Paul Freemont (Im...
Synthetic biology lab backed by £2 million award
Scientists at the University of Liverpool have been awarded £2M to build a state-of-the-art DNA synthesis facility, a capability offering much needed tools for genome engineering to the academic and private sectors.